BRIEF—Anaveon appoints new chief medical officer

Former Innovent Biologics president Eduard Gasal has been appointed as chief medical officer at Swiss immuno-oncology company Anaveon.

Dr Gasal also has experience as a global program clinical head at Novartis, leading a clinical team working on the firm’s melanoma and prostate cancer franchise.

Commenting on Anaveon’s lead program, Dr Gasal said: “ANV419’s differentiated profile is exciting and allows the delivery of high dose IL-2 to patients with a tolerable safety profile.”

He added: “I look forward to working with the Anaveon team to advance the existing development program to the next stage whilst broadening the pipeline with new programs and in new indications.”

The company is seeking to advance ANV419 through development in multiple tumor types.